RxDoctor Payments DataLook up a doctor →

Chris Bajaj, DO

Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1164454369

Payments from drug & device makers

$784,887in general payments, 2019–2025

Across 2,184 payments — averaging $359.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$329K
  • Lilly USA, LLC$146K
  • Insulet Corporation$107K
  • Dexcom, Inc.$68K
  • Kowa Research Institute, Inc.$50K
  • Takeda Pharmaceuticals U.S.A., Inc.$31K
  • plus $53K from 54 others
$1,943in research payments, 2019–2025

Across 8 payments — averaging $242.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS706$329,057
Lilly USA, LLC313$145,931
Insulet Corporation187$107,114
Dexcom, Inc.126$68,407
Kowa Research Institute, Inc.29$50,118
Takeda Pharmaceuticals U.S.A., Inc.31$30,924
Astrazeneca UK Limited4$11,793
Eli Lilly25$10,831
Shire North American Group Inc6$6,258
Tandem Diabetes Care, Inc.24$5,217
Valeritas, Inc.15$3,901
AstraZeneca(2 entities)94$3,183
Abbott73$1,496
Novo Nordisk111$1,230
Ascendis Pharma Endocrinology Inc2$1,206
Amgen(2 entities)46$900
Sanofi-aventis U.S. LLC39$738
AbbVie40$666
Boehringer Ingelheim36$534
Mannkind Corporation19$505
Xeris Pharmaceuticals, Inc.25$385
Amarin Pharma, Inc.20$336
BETA Bionics, Inc.8$324
Sequel Med Tech, LLC15$268
Nevro Corp.11$252
Corcept Therapeutics13$245
Merck15$218
Companion Medical, Inc.10$217
Neurocrine Biosciences, Inc.8$202
Medtronic(2 entities)13$193
Antares Pharma, Inc.11$173
Ultragenyx Pharmaceutical Inc.11$171
Pfizer10$162
Cequr Corporation3$139
Alvogen Inc7$138
Amneal Pharmaceuticals LLC8$129
Bayer8$122
Radius Health, Inc.5$110
Chiesi USA, Inc.4$87
Novartis3$79
Tolmar, Inc.5$77
IBSA Pharma Inc.4$68
Bigfoot Biomedical Inc1$68
Kyowa Kirin, Inc.3$63
Eisai Inc.2$59
Clarus Therapeutics Inc.5$58
Ascensia Diabetes Care US Inc.3$57
Currax Pharmaceuticals LLC4$53
Recordati_rare_diseases_inc.2$41
Vivus LLC3$38
Acerus Pharmaceuticals Corporation2$37
Acella Pharmaceuticals, LLC2$33
Zealand Pharma US, Inc.2$31
Bolton Medical Inc1$28
Ipsen Biopharmaceuticals, Inc1$25
GRT US Holding, Inc.1$23
Halozyme Inc1$22
Strongbridge US Inc.1$20
Intuity Medical Inc1$20
BD1$20

How this compares

$784,887 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$232,786
Medicare patients
623
Services billed
2,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Fort Worth

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →